These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 39399879)

  • 1. TV-46000, A Long-Acting Subcutaneous Antipsychotic Agent, Demonstrated Improved Patient-Centered Outcomes in Patients with Schizophrenia.
    Citrome L; Suett M; Franzenburg KR; Eshet R; Elgart A; Davis Rd GL; Harary E; Tohami O; Mychaskiw MA; Kane JM
    Neuropsychiatr Dis Treat; 2024; 20():1901-1917. PubMed ID: 39399879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial.
    Kane JM; Eshet R; Harary E; Tohami O; Elgart A; Knebel H; Sharon N; Suett M; Franzenburg KR; Davis GL; Correll CU
    CNS Drugs; 2024 Aug; 38(8):625-636. PubMed ID: 38954317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria.
    Kane JM; Harary E; Eshet R; Tohami O; Weiser M; Leucht S; Merenlender-Wagner A; Sharon N; Davis GL; Suett M; Franzenburg KR; Correll CU
    Lancet Psychiatry; 2023 Dec; 10(12):934-943. PubMed ID: 37924833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia.
    Robinson DG; Suett M; Wilhelm A; Chaijale N; Franzenburg KR; Gandhi S; Cloud B; Mychaskiw M
    Adv Ther; 2023 May; 40(5):2249-2264. PubMed ID: 36905498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study.
    Isitt JJ; Nadipelli VR; Kouassi A; Fava M; Heidbreder C
    Schizophr Res; 2016 Jul; 174(1-3):126-131. PubMed ID: 27066860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM.
    Litman R; Naber D; Anta L; Martínez J; Filts Y; Correll CU
    Neuropsychiatr Dis Treat; 2023; 19():219-232. PubMed ID: 36721796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia: Results From the Phase 3 Program.
    Andorn A; Graham J; Csernansky J; Newcomer JW; Shinde S; Muma G; Heidbreder C; Fava M
    J Clin Psychopharmacol; 2019; 39(5):428-433. PubMed ID: 31343440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study.
    Filts Y; Litman RE; Martínez J; Anta L; Naber D; Correll CU
    Schizophr Res; 2022 Jan; 239():83-91. PubMed ID: 34847501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
    Yıldız M; Osman E
    Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine.
    Patel P; Teichner P; Elliot E; Boffito M; Murray M; Polli JW; Baker M; Ford SL; Han K; Russu A; Crauwels H; D'Amico RD; Spreen WR; van Wyk J
    Ther Adv Infect Dis; 2023; 10():20499361231214626. PubMed ID: 38107552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-year Outcomes After Conversion From Monthly to Every 2-month Belatacept Maintenance Therapy in Kidney Transplant Recipients: Results From a Randomized Controlled Trial.
    Johnson AC; Karadkhele GM; Shenvi N; Easley KA; Larsen CP; Badell IR
    Transplant Direct; 2023 Mar; 9(3):e1449. PubMed ID: 36875938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risperidone (depot) for schizophrenia.
    Sampson S; Hosalli P; Furtado VA; Davis JM
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD004161. PubMed ID: 27078222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Every 2-month belatacept maintenance therapy in kidney transplant recipients greater than 1-year posttransplant: A randomized, noninferiority trial.
    Badell IR; Parsons RF; Karadkhele G; Cristea O; Mead S; Thomas S; Robertson JM; Kim GS; Hanfelt JJ; Pastan SO; Larsen CP
    Am J Transplant; 2021 Sep; 21(9):3066-3076. PubMed ID: 33583120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
    Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
    Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study.
    Calabrese JR; Jin N; Johnson B; Such P; Baker RA; Madera J; Hertel P; Ottinger J; Amatniek J; Kawasaki H
    Int J Bipolar Disord; 2018 Jun; 6(1):14. PubMed ID: 29886522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-Year Outcomes of 6-Month Paliperidone Palmitate in Adults With Schizophrenia: An Open-Label Extension Study of a Randomized Clinical Trial.
    Correll CU; Johnston K; Turkoz I; Gray J; Sun L; Doring M; Sajatovic M
    JAMA Netw Open; 2024 Jul; 7(7):e2421495. PubMed ID: 39018073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetic Modeling and Simulation of TV-46000: A Long-Acting Injectable Formulation of Risperidone.
    Perlstein I; Merenlender Wagner A; Gomeni R; Lamson M; Harary E; Spiegelstein O; Kalmanczhelyi A; Tiver R; Loupe P; Levi M; Elgart A
    Clin Pharmacol Drug Dev; 2022 Jul; 11(7):865-877. PubMed ID: 35245409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies.
    Kane JM; Sanchez R; Baker RA; Eramo A; Peters-Strickland T; Perry PP; Johnson BR; Tsai LF; Carson WH; McQuade RD; Fleischhacker WW
    Clin Schizophr Relat Psychoses; 2015; 9(2):79-87. PubMed ID: 25711509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval.
    Gharabawi GM; Gearhart NC; Lasser RA; Mahmoud RA; Zhu Y; Mannaert E; Naessens I; Bossie CA; Kujawa M; Simpson GM
    Ann Gen Psychiatry; 2007 Jan; 6():3. PubMed ID: 17261186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.